{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:23:53Z","timestamp":1791343433444,"version":"4.3.1"},"reference-count":70,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2013,4,22]],"date-time":"2013-04-22T00:00:00Z","timestamp":1366588800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0062438","type":"journal-article","created":{"date-parts":[[2013,4,23]],"date-time":"2013-04-23T03:04:24Z","timestamp":1366686264000},"page":"e62438","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Neonatal Disruption of Serine Racemase Causes Schizophrenia-Like Behavioral Abnormalities in Adulthood: Clinical Rescue by D-Serine"],"prefix":"10.1371","volume":"8","author":[{"given":"Hiroko","family":"Hagiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Iyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,4,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"DC Javitt","year":"1991","journal-title":"Am J Psychiatry"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/hrp.7.3.125","article-title":"NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders","volume":"7","author":"JH Krystal","year":"1999","journal-title":"Harv Rev Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00213-003-1709-2","article-title":"The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia","volume":"174","author":"JT Coyle","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/scientificamerican0104-48","article-title":"Decoding schizophrenia","volume":"290","author":"DC Javitt","year":"2004","journal-title":"Sci Am"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/1573400054065569","article-title":"Dysfunction of glia-neuron communication in pathophysiology of schizophrenia","volume":"1","author":"K Hashimoto","year":"2005","journal-title":"Curr Psychiatry Rev"},{"key":"ref6","first-page":"3","article-title":"The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs","volume":"4","author":"K Hashimoto","year":"2006","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1073\/pnas.96.2.721","article-title":"Purification of serine racemase: biosynthesis of the neuromodulator D-serine","volume":"96","author":"H Wolosker","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"13409","DOI":"10.1073\/pnas.96.23.13409","article-title":"Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission","volume":"96","author":"H Wolosker","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00726-012-1370-3","article-title":"Serine racemase: an unconventional enzyme for an unconventional transmitter","volume":"43","author":"H Wolosker","year":"2012","journal-title":"Amino Acids"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"14486","DOI":"10.1523\/JNEUROSCI.5034-08.2008","article-title":"NMDA- and \u03b2-amyloid<sub>1\u201342<\/sub>-induced neurotoxicity is attenuated in serine racemase knock-out mice","volume":"28","author":"R Inoue","year":"2008","journal-title":"J Neurosci"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/mp.2008.130","article-title":"Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior","volume":"14","author":"AC Basu","year":"2009","journal-title":"Mol Psychiatry"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.neuint.2011.08.017","article-title":"Levels of D-serine in the brain and peripheral organs of serine racemase (Srr) knock-out mice","volume":"59","author":"M Horio","year":"2011","journal-title":"Neurochem Int"},{"key":"ref13","unstructured":"Horio M, Mori H, Hashimoto K (in press) Is D-cycloserine a pro-drug for D-serine in the brain? Biol Psychiatry 2012 Aug 7. [Epub ahead of print]."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1471-4159.1993.tb03219.x","article-title":"Endogenous D-serine in rat brain: N-methyl-D-aspartate receptor-related distribution and aging","volume":"60","author":"A Hashimoto","year":"1993","journal-title":"J Neurochem"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1523\/JNEUROSCI.17-05-01604.1997","article-title":"D-Serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptor","volume":"17","author":"MJ Schell","year":"1997","journal-title":"J Neurosci"},{"key":"ref16","first-page":"965","article-title":"Spatiotemporal relationships among D-serine, serine racemase, and D-amino acid oxidase during mouse postnatal development","volume":"24","author":"LZ Wang","year":"2003","journal-title":"Acta Pharmacol Sci"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/138161211795049633","article-title":"Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia","volume":"17","author":"DV Ferraris","year":"2011","journal-title":"Curr Pharm Des"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.neuropharm.2011.01.030","article-title":"Contributions of the D-serine pathway to schizophrenia","volume":"62","author":"V Labrie","year":"2012","journal-title":"Neuropharmacology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/schbul\/sbs069","article-title":"Has an angel shown the way? Etiological and therapeutic implications of the PCP\/NMDA model of schizophrenia","volume":"38","author":"DC Javitt","year":"2012","journal-title":"Schizophr Bull"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archpsyc.60.6.572","article-title":"Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia","volume":"60","author":"K Hashimoto","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.biopsych.2005.03.018","article-title":"Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels","volume":"57","author":"K Yamada","year":"2005","journal-title":"Biol Psychiatry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.pnpbp.2005.04.023","article-title":"Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients","volume":"29","author":"K Hashimoto","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2006.10.010","article-title":"A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia","volume":"90","author":"I Bendikov","year":"2007","journal-title":"Schizophr Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.schres.2012.09.014","article-title":"Plasma levels of D-serine in Brazillian individuals with schizophrenia","volume":"142","author":"MA Calcia","year":"2012","journal-title":"Schizophr Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0006-3223(98)00279-0","article-title":"D-serine added to antipsychotics for the treatment of schizophrenia","volume":"44","author":"G Tsai","year":"1998","journal-title":"Biol Psychiatry"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.biopsych.2004.12.037","article-title":"D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia","volume":"57","author":"U Heresco-Levy","year":"2005","journal-title":"Biol Psychiatry"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2174\/138161210790361452","article-title":"Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia. A critical review and meta-analysis","volume":"16","author":"GE Tsai","year":"2010","journal-title":"Curr Pham Des"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/j.1460-9568.2007.05769.x","article-title":"D-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia","volume":"26","author":"L Verrall","year":"2007","journal-title":"Eur J Neurosci"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.schres.2008.02.002","article-title":"Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia","volume":"101","author":"C Madeira","year":"2008","journal-title":"Schizophr Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"13675","DOI":"10.1073\/pnas.182412499","article-title":"Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia","volume":"99","author":"I Chumakov","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/sj.mp.4002052","article-title":"Evidence implicating the candidate schizophrenia\/bipolar disorder susceptibility gene G72 in mitochondrial function","volume":"13","author":"M Kvajo","year":"2008","journal-title":"Mol Psychiatry"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.biopsych.2006.01.019","article-title":"G72\/G30 in schizophrenia and bipolar disorder: review and meta-analysis","volume":"60","author":"SD Detetra-Wadleigh","year":"2006","journal-title":"Biol Psychiatry"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archpsyc.1987.01800190080012","article-title":"Implications of normal brain development for the pathogenesis of schizophrenia","volume":"44","author":"DR Weinberger","year":"1987","journal-title":"Arch Gen Psychiatry"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1001\/archpsyc.1996.01830010013003","article-title":"Neurodevelopmental abnormalities and schizophrenia. A family affair","volume":"53","author":"RJ Wyatt","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/07853890310010005","article-title":"The neurodevelopmental hypothesis of schizophrenia: a review of recent developments","volume":"35","author":"JJ McGrath","year":"2003","journal-title":"Ann Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1073\/pnas.0409723102","article-title":"Serine racemase: activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration","volume":"102","author":"PM Kim","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/bmc.394","article-title":"Simultaneous determination of D- and L-serine in rat brain microdialysis sample using a column-switching HPLC with fluorimetric detection","volume":"18","author":"T Fukushima","year":"2004","journal-title":"Biomed Chromatogr"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-244X-5-6","article-title":"Elevated glutamine\/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients","volume":"5","author":"K Hashimoto","year":"2005","journal-title":"BMC Psychiatry"},{"key":"ref39","first-page":"1310","article-title":"Increased levels of glutamate in brains from patients with mood disorders. Biol","volume":"62","author":"K Hashimoto","year":"2007","journal-title":"Psychiatry"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.biopsych.2005.07.031","article-title":"Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia","volume":"59","author":"K Ozawa","year":"2006","journal-title":"Biol Psychiatry"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1038\/sj.npp.1301313","article-title":"Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine","volume":"32","author":"L Zhang","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.brainres.2009.09.010","article-title":"Mithramycin protects dopaminergic neurotoxicity in mouse brain after administration of methamphetamine","volume":"1301","author":"H Hagiwara","year":"2009","journal-title":"Brain Res"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2005.07.002","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol","volume":"519","author":"K Hashimoto","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.npp.1301047","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: Role of sigma-1 receptors","volume":"32","author":"K Hashimoto","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.biopsych.2007.04.034","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective \u03b17 nicotinic receptor agonist SSR180711","volume":"63","author":"K Hashimoto","year":"2008","journal-title":"Biol Psychiatry"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.biopsych.2009.01.002","article-title":"Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine","volume":"65","author":"K Hashimoto","year":"2009","journal-title":"Biol Psychiatry"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0893-133X(97)00200-5","article-title":"Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats","volume":"19","author":"F Sams-Dodd","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00008877-200311000-00006","article-title":"Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits","volume":"14","author":"S Mandillo","year":"2003","journal-title":"Behav Pharmacol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0920-9964(97)00102-3","article-title":"Neuropsychological correlates of positive vs. negative schizophrenic symptomatology","volume":"29","author":"KK Zakzanis","year":"1998","journal-title":"Schizophr Res"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2005.07.002","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol","volume":"519","author":"K Hashimoto","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.euroneuro.2007.07.009","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of glycine transporter-1 inhibitor NFPS and D-serine","volume":"18","author":"K Hashimoto","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/archpsyc.1990.01810140081011","article-title":"Sensorimotor gating and schizophrenia. Human and animal model studies","volume":"47","author":"DL Braff","year":"1990","journal-title":"Arch Gen Psychiatry"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0006-3223(01)01303-8","article-title":"The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches","volume":"50","author":"JA Lieberman","year":"2001","journal-title":"Biol Psychiatry"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0920-9964(03)00214-7","article-title":"Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia","volume":"68","author":"T Lencz","year":"2004","journal-title":"Schizophr Res"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1176\/appi.ajp.2011.10081209","article-title":"Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis","volume":"168","author":"RE Carri\u00f3n","year":"2011","journal-title":"Am J Psychiatry"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.4088\/JCP.08r04472","article-title":"Intervention in individuals at ultra-high risk for psychosis: a review and future directions","volume":"70","author":"PD McGorry","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1001\/archgenpsychiatry.2011.1592","article-title":"Cognitive functioning in prodromal psychosis: a meta-analysis","volume":"69","author":"P Fusar-Poli","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"ref58","first-page":"82","article-title":"Preventive pharmacological treatment \u2013 An evolving new concept in schizophrenia","volume":"48","author":"R Sabbag","year":"2011","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"ref59","unstructured":"Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, et al. (in press) Glycine treatment of the risk syndrome for psychosis: Report of two pilots studies. Eur Neuropsychopharmacol 2012 Oct 19. doi:pii: S0924\u2013977X(12)00272\u20136. 10.1016\/j.euroneuro.2012.09.008. [Epub ahead of print]."},{"key":"ref60","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.schres.2010.05.012","article-title":"High dose of D-serine in the treatment of schizophrenia","volume":"121","author":"JT Kantrowitz","year":"2010","journal-title":"Schizophr Res"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.brainresrev.2009.05.005","article-title":"Emerging role of glutamate in the pathophysiology of major depressive disorder","volume":"61","author":"K Hashimoto","year":"2009","journal-title":"Brain Res Rev"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1471-4159.2010.07039.x","article-title":"Analyses of mechanism for mouse strain-dependent prepulse inhibition point to a role of <italic>Shmt1<\/italic> (<italic>SHMT1<\/italic>) in mice and schizophrenia","volume":"115","author":"T Maekawa","year":"2010","journal-title":"J Neurochem"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Hashimoto K, Malchow B, Falkai P, Schmitt P (in press) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 2013 Mar 1. [Epub ahead of print].","DOI":"10.1007\/s00406-013-0399-y"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/jnr.490300316","article-title":"Redox modulatory site of the NMDA receptor-channel complex: Regulation by oxidized glutathione","volume":"30","author":"NJ Sucher","year":"1991","journal-title":"J Neurosci Res"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0896-6273(94)90311-5","article-title":"NMDA receptor channels: Subunit-specific potentiation by reducing agents","volume":"12","author":"G Kohr","year":"1994","journal-title":"Neuron"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1023\/A:1027377605054","article-title":"Glutathione is an endogenous ligand of rat brain N-methyl-D-aspartate (NMDA) and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors","volume":"22","author":"V Varga","year":"1997","journal-title":"Neurochem Res"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"e1944","DOI":"10.1371\/journal.pone.0001944","article-title":"Negative correlation between brain glutathione levels and negative symptoms in schizophrenia: a 3T <sup>1<\/sup>H-MRS study","volume":"3","author":"D Matsuzawa","year":"2008","journal-title":"PLoS ONE"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.biopsych.2008.06.025","article-title":"Correspondence: Regarding \u201cN-Acetyl cysteine as a glutathione precursor for schizophrenia \u2013 a double-blind, randomized, placebo-controlled trial\u201d","volume":"64","author":"K Hashimoto","year":"2008","journal-title":"Biol Psychiatry"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1089\/ars.2010.3453","article-title":"Magnetic resonance spectroscopy study of antioxidant defense system in schizophrenia","volume":"Sig15","author":"D Matsuzawa","year":"2011","journal-title":"Antioxi Redox"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.conb.2009.05.001","article-title":"Redox dysregulation, neurodevelopment, and schizophrenia","volume":"19","author":"KQ Do","year":"2009","journal-title":"Curr Opin Neurobiol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0062438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T23:12:48Z","timestamp":1562973168000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0062438"}},"subtitle":[],"editor":[{"given":"Xiang Yang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,4,22]]},"references-count":70,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,4,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0062438","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,22]]}}}